.png){kind=icon}
J
Jelena Čelutkienė
H指数:56
被引数:4.5万
浏览量:0
个人简介
暂无内容
教育背景
暂无内容
工作经历
暂无内容
荣誉奖项
暂无内容
Multimodality imaging in the detection and management of coronary and peripheral arterial disease in patients with cancer receiving cardiotoxic antineoplastic treatments: A clinical consensus statement of the ESC Council of Cardio-Oncology and the European Association of Cardiovascular Imaging (EACVI) of the ESC
癌症患者在接受心脏毒性抗肿瘤治疗时，冠状动脉和外周动脉疾病的检测与管理中的多模态成像：欧洲心脏病学会心血管影像学协会（EACVI）和欧洲心脏病学会心血管影像学协会（EACVI）心血管肿瘤学委员会的临床共识声明
Atrial cardiomyopathy: From healthy atria to atrial failure. A clinical consensus statement of the Heart Failure Association of the ESC
心房心肌病：从健康心房到心房衰竭。欧洲心脏病学会心力衰竭协会临床共识声明
Coronary anatomic, functional, and prognostic correlates of ischemic electrocardiographic changes during stress echocardiography
负荷超声心动图期间缺血性心电图变化的冠状动脉解剖、功能和预后相关性
Insights on prevalence and incidence of anemia and rapid up-titration of oral heart failure treatment from the STRONG-HF study
从stronte-hf研究中了解贫血的患病率和发生率以及口服心力衰竭治疗的快速滴定
Heart failure in Europe: Guideline-directed medical therapy use and decision making in chronic and acute, pre-existing and de novo, heart failure with reduced, mildly reduced, and preserved ejection fraction - the ESC EORP Heart Failure III Registry
欧洲的心力衰竭: 指南指导下的慢性和急性，先前存在和从头开始的心力衰竭，射血分数降低，轻度降低和保留的心力衰竭的药物治疗使用和决策-ESC EORP心力衰竭III注册表
Characteristics, treatment, and outcomes of early vs. late enrollees of the STRONG-HF trial
STRONG-HF试验早期与晚期入选者的特征、治疗和结局
Biologically active adrenomedullin as a marker for residual congestion and early rehospitalization in patients hospitalized for acute heart failure: Data from STRONG-HF
具有生物活性的肾上腺髓质素可作为急性心力衰竭住院患者残余充血和早期再住院的标志物: 来自强HF的数据
